Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03090685
Other study ID # U1111-1193-8428
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 5, 2017
Est. completion date November 1, 2017

Study information

Verified date October 2018
Source Universidade Federal do Ceara
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chikungunya fever is an acute viral disease, transmitted by the mosquito (Aedes aegypti), that triggers pain and disabling rheumatic manifestations. There is no cure for this disease, and the usual treatment is directed at relieving symptoms through the use of analgesics and antipyretics. Due to the risk of adverse effects triggered by prolonged use of analgesic and anti-inflammatory drugs, the use of complementary therapies, such as Auriculotherapy, might be a safe and effective non-pharmacological treatment for the management of Chikungunya symptomatic cases.

Subjects diagnosed with Chikungunya and undergoing routine treatment will receive auricotherapy treatment once a week, for five weeks. Subjects will be assessed at baseline and after 4 and 8 weeks after intervention. This study might help understand the use of Auriculotherapy as a complementary treatment in the treatment of physical and functional symptoms of individuals infected by Chikungunya .


Description:

Objectives of the study

1. To evaluate the effectiveness of Auriculotherapy in the management of pain and functional capacity of symptomatic individuals after Chikungunya fever.

2. To evaluate the effects of Auriculotherapy on the intensity of pain, limitation of mobility, and perception of disability and physical capacity.

3. Investigate the effect of Auriculotherapy on pain medication use.

Place and study population: Subjects diagnosed with Chikungunya Fever will be recruited for convenience in the basic care of the city of Fortaleza-CE, Brazil, in order to be evaluated and treated by the researcher's team.

Procedures and intervention: Subjects will be evaluated at the initial time of the research, and after 4 and 8 weeks of intervention. The description of the procedures will follow the guidelines of the Consolidated Standards of Reporting Trials (CONSORT) and the Standards for Reporting Interventions in Controlled Trials of Acupuncture (STRICTA). Asepsis of the ear with alcohol 70%is necessary to apply 4 to 5 auricular acupuncture points. In the intervention group, specific points will be used to the management of pain and physical function. In the placebo group, non-specific points will be used. Patients will be instructed to exert finger pressure at each point for 3 minutes. At least 3x / day, or whenever they feel pain. These implants will be kept for 5 days and will be taken off by the participant 2 days before the next appointment.

Ethical aspects: The research will begin after approval by the Ethics and Research Committee (CEP) of the Federal University of CearĂ¡. All participants will sign the Informed Consent and are free to withdraw from the study.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date November 1, 2017
Est. primary completion date November 1, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria:

- individuals aged = 18 years;

- with medical or other referral from the Family Health Strategy due to symptoms resulting from Chikungunya fever confirmed by clinical or laboratory criteria;

- be able to understand instructions and answer the questions asked by the interviewer.

Exclusion Criteria:

- complaints of pain unrelated to the lower limbs;

- presence of malignant neoplastic disease;

- history of traumatic injury or the lower limb and surgery in the last 12 months;

- congenital deformation;

- pregnancy;

- history of treatment with with Auriculotherapy, acupuncture or physiotherapy in the last four weeks;

- use of steroid medication in the last month;

- use of opioids during the study period;

- do not sign the Free and Informed Consent Form (TCLE).

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
True auriculotherapy with seeds
Roasted edible mustard seeds with ~ 2mm diameter fixed with adhesive tape in 4 to 5 specific body points to control musculoskeletal pain.
Placebo Auriculotherapy with seeds
Roasted edible mustard seeds with ~ 2mm diameter fixed with adhesive tape at 4 points located in the auricular lobe not specific for musculoskeletal pain.

Locations

Country Name City State
Brazil Grupo de Atenção Integral e Pesquisa em Acupuntura e Medicina Tradicional Chinesa - GAIPA Fortaleza Ceará

Sponsors (1)

Lead Sponsor Collaborator
Universidade Federal do Ceara

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain Numerical rating scale (NRS) Graded scale from 0 (no pain) to 10 (worst pain imaginable) that evaluates in one-dimensional the perception of pain by asking about the average pain felt in the past seven days in the symptomatic limb. collected at baseline up to 2 months after therapy
Primary Timed Up and Go Test (TUG) Performance-based test designed to assess functional mobility and risk of falls in frail older adults.This instrument has been associated with other to test musculoskeletal conditions. collected at baseline up to 2 months after therapy
Secondary World Health Disability Assessment Schedule (WHODAS 2.0) Generic instrument with high internal consistency (a: 0.86), high test-retest reliability (ICC: 0.98) that evaluates deficiency and functionality based on six domains (cognition, mobility, self-care, interpersonal relations, life activity and participation). collected at baseline up to 2 months after therapy
Secondary Short Physical Performance Battery (SPPB) Test consisted of thress sub-tests that assess the functional capacity of the lower limbs, through static balance, gait speed and lower limb muscle strength. collected at baseline up to 2 months after therapy
Secondary Reducing the use of pain medication Patient self-report on the use of analgesic and anti-inflammatory drugs, by recording the dosage and type of medication. collected at baseline up to 2 months after therapy
See also
  Status Clinical Trial Phase
Terminated NCT03055585 - Applying Wolbachia to Eliminate Dengue N/A
Withdrawn NCT02714985 - RT-PCR on Urine Samples: Added Value for the Diagnosis of Chikungunya Virus Infection
Completed NCT02901509 - Impact of the Chikungunya Outbreak in Reunion Island on the Quality of Life After 10 Years
Completed NCT03590392 - Safety and Immunogenicity of a Candidate CHIKV Vaccine (CHIK001) Phase 1
Active, not recruiting NCT03702348 - Resistance Exercise Program on the Functionality of Individuals With Chikungunya Fever Early Phase 1
Not yet recruiting NCT04235361 - Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRC
Completed NCT03206541 - Neurologic Manifestations of the Arbovirus Infection in Colombia
Completed NCT06268691 - Sustainable Reduction of Dengue in Colombia: Vector Breeding Site Intervention With an Insecticidal Coating N/A
Completed NCT01489358 - Chikungunya Virus Vaccine Trial in Healthy Adults Phase 1
Completed NCT02993952 - tDCS and Its Therapeutic Effects in CK Fever N/A
Completed NCT03690648 - Genetic Factors and Immunological Determinism of Persistent Consequences of Chikungunya
Completed NCT02174341 - The Pilot Study of Chikungunya Virus Infections in Southern Taiwan